The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement
Open accessThe DOI matches its Crossref record; 131 of the 131 references it cites were found in a registry or an index.
Abstract
Anti-tumour necrosis factor (TNF) monoclonal antibodies or soluble TNF receptors have become an invaluable treatment against chronic inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. Individuals who are treated with TNF antagonists are at an increased risk of reactivating latent infections, especially tuberculosis (TB). Following TNF antagonist therapy, the relative risk for TB is increased up to 25 times, depending on the clinical setting and the TNF antagonist used. Interferon-γ release assays or, as an alternative in individuals without a history of bacille Calmette–Guérin vaccination, tuberculin skin testing is recommended to screen all adult candidates for TNF antagonist treatment for the presence of latent infection with Mycobacterium tuberculosis. Moreover, paediatric practice suggests concomitant use of both the tuberculin skin test and an interferon-γ release assay, as there are insufficient data in children to recommend one test over the other. Consequently, targeted preventive chemotherapy is highly recommended for all individuals with persistent M. tuberculosis-specific immune responses undergoing TNF antagonist therapy as it significantly reduces the risk of progression to TB. This TBNET consensus statement summarises current knowledge and expert opinions and provides evidence-based recommendations to reduce the TB risk among candidates for TNF antagonist therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Self-citationInfliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Colombel, J. F., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rachmilewitz, D., Lichtiger, S., D'Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,143
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Tumor necrosis factor signaling
Wajant, H., Pfizenmaier, K., & Scheurich, P. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401189 · Cited by 2,359
Colombel, J., Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Panaccione, R., Schreiber, S., Byczkowski, D., Li, J., Kent, J. D., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.041 · Cited by 2,245
Self-citationFlynn, J. L., & Chan, J. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.93 · Cited by 2,155
Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90628-9 · Cited by 1,682
Flynn, J. L., Goldstein, M. M., Chan, J., Triebold, K. J., Pfeffer, K., Lowenstein, C. J., Schrelber, R., Mak, T. W., & Bloom, B. R. (1995) · Immunity · doi:10.1016/1074-7613(95)90001-2 · Cited by 1,677
Signal transduction by tumor necrosis factor and its relatives
Baud, V., & Karin, M. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)02064-5 · Cited by 1,655
The spectrum of latent tuberculosis: rethinking the biology and intervention strategies
Barry, C. E., Boshoff, H. I., Dartois, V., Dick, T., Ehrt, S., Flynn, J., Schnappinger, D., Wilkinson, R. J., & Young, D. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2236 · Cited by 1,422
Systematic Review: T-Cell–based Assays for the Diagnosis of Latent Tuberculosis Infection: An Update
Pai, M., Zwerling, A., & Menzies, D. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-3-200808050-00241 · Cited by 1,339
Braun, J., Brandt, J., Listing, J., Zink, A., Alten, R., Golder, W., Gromnica-lhle, E., Kellner, H., Krause, A., Schneider, M., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08215-6 · Cited by 1,261
Kindler, V., Sappino, A.-P., Grau, G. E., Piguet, P.-F., & Vassalli, P. (1989) · Cell · doi:10.1016/0092-8674(89)90676-4 · Cited by 1,254
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.supplement_3.ats600 · Cited by 1,241
Etanercept as Monotherapy in Patients with Psoriasis
Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030409 · Cited by 1,175
Saag, K. G., Teng, G. G., Patkar, N. M., Anuntiyo, J., Finney, C., Curtis, J. R., Paulus, H. E., Mudano, A., Pisu, M., Elkins‐Melton, M., et al. (2008) · Arthritis Care & Research · doi:10.1002/art.23721 · Cited by 1,157
Certolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,143
Self-citationMolecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis
Mahairas, G. G., Sabo, P. J., Hickey, M. J., Singh, D. C., & Stover, C. K. (1996) · Journal of Bacteriology · doi:10.1128/jb.178.5.1274-1282.1996 · Cited by 1,103
Hehlgans, T., & Pfeffer, K. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02143.x · Cited by 1,048
Reich, K., Nestle, F. O., Papp, K., Ortonne, J.-P., Evans, R., Guzzo, C., Li, S., Dooley, L. T., & Griffiths, C. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67566-6 · Cited by 1,045
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease
Schreiber, S., Khaliq-Kareemi, M., Lawrance, I. C., Thomsen, O. Ø., Hanauer, S. B., McColm, J., Bloomfield, R., & Sandborn, W. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062897 · Cited by 1,043
Self-citationGómez‐Reino, J. J., Carmona, L., Valverde, V. R., Mola, E. M., & Montero, M. D. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11137 · Cited by 1,013
Self-citationMenzies, D., Pai, M., & Comstock, G. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-5-200703060-00006 · Cited by 984
Specific immune-based diagnosis of tuberculosis
Andersen, P., Munk, M., Pollock, J., & Doherty, T. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02742-2 · Cited by 924
Huebner, R. E., Schein, M. F., & Bass, J. B. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.6.968 · Cited by 917
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Menter, A., Tyring, S. K., Gordon, K., Kimball, A. B., Leonardi, C. L., Langley, R. G., Strober, B. E., Kaul, M., Gu, Y., Okun, M., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.09.010 · Cited by 889
Combe, B., Landewe, R., Lukas, C., Bolosiu, H. D., Breedveld, F., Dougados, M., Emery, P., Ferraccioli, G., Hazes, J. M. W., Klareskog, L., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.044354 · Cited by 786
Roach, D. R., Bean, A. G. D., Demangel, C., France, M. P., Briscoe, H., & Britton, W. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4620 · Cited by 782
Dixon, W. G., Watson, K., Lunt, M., Hyrich, K. L., Silman, A. J., & Symmons, D. P. M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21978 · Cited by 751
How can immunology contribute to the control of tuberculosis?
Kaufmann, S. H. E. (2001) · Nature Reviews Immunology · doi:10.1038/35095558 · Cited by 729
Van den Brande, J. M. H., Braat, H., van den Brink, G. R., Versteeg, H. H., Bauer, C. A., Hoedemaeker, I., van Montfrans, C., Hommes, D. W., Peppelenbosch, M. P., & van Deventer, S. J. H. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00382-2 · Cited by 723
Dixon, W. G., Hyrich, K. L., Watson, K. D., Lunt, M., Galloway, J., Ustianowski, A., & Symmons, D. P. M. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.118935 · Cited by 715
Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists
Scallon, B., Cai, A., Solowski, N., Rosenberg, A., Song, X.-Y., Shealy, D., & Wagner, C. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.418 · Cited by 672
Carmona, L., Gómez‐Reino, J. J., Rodríguez‐Valverde, V., Montero, D., Pascual‐Gómez, E., Mola, E. M., Carreño, L., Figueroa, M., & BIOBADASER Group (2005) · Arthritis & Rheumatism · doi:10.1002/art.21043 · Cited by 656
Self-citationTubach, F., Salmon, D., Ravaud, P., Allanore, Y., Goupille, P., Bréban, M., Pallot‐Prades, B., Pouplin, S., Sacchi, A., Chichemanian, R. M., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24632 · Cited by 632
Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis
Lovell, D. J., Ruperto, N., Goodman, S., Reiff, A., Jung, L., Jarosova, K., Nemcova, D., Mouy, R., Sandborg, C., Bohnsack, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706290 · Cited by 625
Bean, A. G. D., Roach, D. R., Briscoe, H., France, M. P., Korner, H., Sedgwick, J. D., & Britton, W. J. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.6.3504 · Cited by 618
Mack, U., Migliori, G. B., Sester, M., Rieder, H. L., Ehlers, S., Goletti, D., Bossink, A., Magdorf, K., Hölscher, C., Kampmann, B., et al. (2009) · European Respiratory Journal · doi:10.1183/09031936.00120908 · Cited by 591
Self-citationvan der Heijde, D., Landewé, R., Einstein, S., Ory, P., Vosse, D., Ni, L., Lin, S. ‐., Tsuji, W., & Davis, J. C. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23471 · Cited by 549
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease
ten Hove, T. (2002) · Gut · doi:10.1136/gut.50.2.206 · Cited by 545
Mohan, V. P., Scanga, C. A., Yu, K., Scott, H. M., Tanaka, K. E., Tsang, E., Tsai, M. C., Flynn, J. L., & Chan, J. (2001) · Infection and Immunity · doi:10.1128/iai.69.3.1847-1855.2001 · Cited by 536
Menter, A., Feldman, S. R., Weinstein, G. D., Papp, K., Evans, R., Guzzo, C., Li, S., Dooley, L. T., Arnold, C., & Gottlieb, A. B. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.07.017 · Cited by 516
Heijde, D. V. D., Landewé, R., Baraliakos, X., Houben, H., Tubergen, A. V., Williamson, P., Xu, W., Baker, D., Goldstein, N., & Braun, J. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23901 · Cited by 514
Gordon, K. B., Langley, R. G., Leonardi, C., Toth, D., Menter, M. A., Kang, S., Heffernan, M., Miller, B., Hamlin, R., Lim, L., et al. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.05.027 · Cited by 510
Measurement of Delayed Skin-Test Responses
Sokal, J. E. (1975) · New England Journal of Medicine · doi:10.1056/nejm197509042931013 · Cited by 500
van Pittius, N. C. G., Sampson, S. L., Lee, H., Kim, Y., van Helden, P. D., & Warren, R. M. (2006) · BMC Evolutionary Biology · doi:10.1186/1471-2148-6-95 · Cited by 483
Newton, S. M., Brent, A. J., Anderson, S., Whittaker, E., & Kampmann, B. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70182-8 · Cited by 480
Self-citationNesbitt, A., Fossati, G., Bergin, M., Stephens, P., Stephens, S., Foulkes, R., Brown, D., Robinson, M., & Bourne, T. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20225 · Cited by 477
British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009
Smith, C. H., Anstey, A. V., Barker, J. N. W. N., Burden, A. D., Chalmers, R. J. G., Chandler, D. A., Finlay, A. Y., Griffiths, C. E. M., Jackson, K., McHugh, N. J., et al. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09505.x · Cited by 464
Comparison of Treatment Strategies in Early Rheumatoid Arthritis: A Randomized Trial
Goekoop-Ruiterman, Y. P. M., de Vries-Bouwstra, J. K., Allaart, C. F., van Zeben, D., Kerstens, P. J. S. M., Hazes, J. M. W., Zwinderman, A. H., Peeters, A. J., de Jonge-Bok, J. M., Mallée, C., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-6-200703200-00005 · Cited by 448
British Thoracic Society Standards of Care Committee (2005) · Thorax · doi:10.1136/thx.2005.046797 · Cited by 432
Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy
Wolfe, F., Michaud, K., Anderson, J., & Urbansky, K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20009 · Cited by 431
Rapid Detection of Mycobacterium tuberculosis Infection by Enumeration of Antigen-specific T Cells
LALVANI, A., PATHAN, A. A., McSHANE, H., WILKINSON, R. J., LATIF, M., CONLON, C. P., PASVOL, G., & HILL, A. V. S. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.4.2009100 · Cited by 427
Askling, J., Fored, C. M., Brandt, L., Baecklund, E., Bertilsson, L., Cöster, L., Geborek, P., Jacobsson, L. T., Lindblad, S., Lysholm, J., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21137 · Cited by 419
Ruperto, N., Lovell, D. J., Cuttica, R., Wilkinson, N., Woo, P., Espada, G., Wouters, C., Silverman, E. D., Balogh, Z., Henrickson, M., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22838 · Cited by 410
Self-citationChen, Y.-F., Jobanputra, P., Barton, P., Jowett, S., Bryan, S., Clark, W., Fry-Smith, A., & Burls, A. (2006) · Health Technology Assessment · doi:10.3310/hta10420 · Cited by 406
Evidence that tumor necrosis factor has an important role in antibacterial resistance.
Havell, E. A. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.9.2894 · Cited by 405
Lalvani, A., Pathan, A. A., Durkan, H., Wilkinson, K. A., Whelan, A., Deeks, J. J., Reece, W. H., Latif, M., Pasvol, G., & Hill, A. V. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05115-1 · Cited by 400
Etanercept Treatment for Children and Adolescents with Plaque Psoriasis
Paller, A. S., Siegfried, E. C., Langley, R. G., Gottlieb, A. B., Pariser, D., Landells, I., Hebert, A. A., Eichenfield, L. F., Patel, V., Creamer, K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa066886 · Cited by 391
Control and prevention of tuberculosis in the United Kingdom: Code of Practice 2000
Joint Tuberculosis Committee of the British Thoracic Society (2000) · Thorax · doi:10.1136/thorax.55.11.887 · Cited by 366
Diel, R., Loddenkemper, R., Meywald-Walter, K., Niemann, S., & Nienhaus, A. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200711-1613oc · Cited by 351
Self-citationDalton, D. K., Haynes, L., Chu, C.-Q., Swain, S. L., & Wittmer, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.1.117 · Cited by 331
Lovell, D. J., Reiff, A. O., Ilowite, N. T., Wallace, C. A., Chon, Y., Lin, S., Baumgartner, S. W., Giannini, E. H., & Pediatric Rheumatology Collaborative Study Group (2008) · Arthritis & Rheumatism · doi:10.1002/art.23427 · Cited by 324
Bruns, H., Meinken, C., Schauenberg, P., Härter, G., Kern, P., Modlin, R. L., Antoni, C., & Stenger, S. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38482 · Cited by 307
Epidemiologic basis of tuberculosis control
Rieder, H. L. (1999) · Cited by 291
Self-citationDetjen, A. K., Keil, T., Roll, S., Hauer, B., Mauch, H., Wahn, U., & Magdorf, K. (2007) · Clinical Infectious Diseases · doi:10.1086/519266 · Cited by 288
Tumor Necrosis Factor-α Inhibitor-Induced Psoriasis or Psoriasiform Exanthemata
Wollina, U., Hansel, G., Koch, A., Schönlebe, J., Köstler, E., & Haroske, G. (2008) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200809010-00001 · Cited by 285
Infections and anti–tumor necrosis factor α therapy
Ellerin, T., Rubin, R. H., & Weinblatt, M. E. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11301 · Cited by 284
Horneff, G., De Bock, F., Foeldvari, I., Girschick, H. J., Michels, H., Moebius, D., & Schmeling, H. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.087593 · Cited by 277
Tumour necrosis factor antagonists: structure, function, and tuberculosis risks
Wallis, R. S. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70227-5 · Cited by 275
Self-citationAntirheumatic Drugs and the Risk of Tuberculosis
Brassard, P., Kezouh, A., & Suissa, S. (2006) · Clinical Infectious Diseases · doi:10.1086/506935 · Cited by 266
Increased risk of tuberculosis in patients with rheumatoid arthritis.
Carmona, L., Hernández‐García, C., Vadillo, C., Pato, E., Balsa, A., González‐Álvaro, I., Belmonte, M. Á., Tena, X., & Sanmartí, R. (2003) · PubMed · Cited by 233
Self-citationMatulis, G., Jüni, P., Villiger, P. M., & Gadola, S. D. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.070789 · Cited by 229
Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept
Shen, C., Assche, G. V., Colpaert, S., Maerten, P., Geboes, K., Rutgeerts, P., & Ceuppens, J. L. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02309.x · Cited by 223
Oh, C. J., Das, K. M., & Gottlieb, A. B. (2000) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2000.105948 · Cited by 222
Prince, F. H. M., Twilt, M., Cate, R. T., van Rossum, M. A. J., Armbrust, W., Hoppenreijs, E. P. A. H., van Santen-Hoeufft, M., Koopman-Keemink, Y., Wulffraat, N. M., & van Suijlekom-Smit, L. W. A. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.087411 · Cited by 221
Granulomatous Infections Due to Tumor Necrosis Factor Blockade: Correction
Wallis, R. S., Broder, M., Wong, J., & Beenhouwer, D. (2004) · Clinical Infectious Diseases · doi:10.1086/424455 · Cited by 219
Self-citationTumor necrosis factor alpha regulates in vivo intrapulmonary expression of ICAM-1.
Mulligan, M. S., Vaporciyan, A. A., Miyasaka, M., Tamatani, T., & Ward, P. A. (1993) · PubMed Central · Cited by 200
Allendoerfer, R., & Deepe, G. S. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.12.6072 · Cited by 197
Winthrop, K. L., Yamashita, S., Beekmann, S. E., Polgreen, P. M., & Infectious Diseases Society of America Emerging Infections Network (2008) · Clinical Infectious Diseases · doi:10.1086/587989 · Cited by 196
McLeod, C., Bagust, A., Boland, A., Dagenais, P., Dickson, R., Dundar, Y., Hill, R., Jones, A., Mujica Mota, R., & Walley, T. (2007) · Health Technology Assessment · doi:10.3310/hta11280 · Cited by 188
Long-term outcome of maintenance infliximab therapy in children with Crohnʼs disease
Hyams, J. S., Lerer, T., Griffiths, A., Pfefferkorn, M., Kugathasan, S., Evans, J., Otley, A., Carvalho, R., Mack, D., Bousvaros, A., et al. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20845 · Cited by 182
Garcia Vidal, C., Rodriguez Fernandez, S., Martinez Lacasa, J., Salavert, M., Vidal, R., Rodriguez Carballeira, M., & Garau, J. (2005) · Clinical Infectious Diseases · doi:10.1086/427941 · Cited by 180
Mycobacterium tuberculosisand the host response
Kaufmann, S. H. E., Cole, S. T., Mizrahi, V., Rubin, E. J., & Nathan, C. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050842 · Cited by 175
GROVES, R. W., ALLEN, M. H., ROSS, E. L., BARKER, J. N. W. N., & MACDONALD, D. M. (1995) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1995.tb08666.x · Cited by 173
Self-citationSaunders, B. M., Tran, S., Ruuls, S. R., Sedgwick, J. D., Briscoe, H., & Britton, W. J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4852 · Cited by 170
Van den Brande, J. M. H., Koehler, T. C., Zelinkova, Z., Bennink, R. J., te Velde, A. A., ten Cate, F. J. W., van Deventer, S. J. H., Peppelenbosch, M. P., & Hommes, D. W. (2007) · Gut · doi:10.1136/gut.2006.105379 · Cited by 170
Haustein, T., Ridout, D. A., Hartley, J. C., Thaker, U., Shingadia, D., Klein, N. J., Novelli, V., & Dixon, G. L. J. (2009) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181a16394 · Cited by 169
Tumor Necrosis Factor and Tuberculosis
Lin, P. L., Plessner, H. L., Voitenok, N. N., & Flynn, J. L. (2007) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1038/sj.jidsymp.5650027 · Cited by 167
Bekker, L.-G., Freeman, S., Murray, P. J., Ryffel, B., & Kaplan, G. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6728 · Cited by 166
Aichelburg, M. C., Rieger, A., Breitenecker, F., Pfistershammer, K., Tittes, J., Eltz, S., Aichelburg, A. C., Stingl, G., Makristathis, A., & Kohrgruber, N. (2009) · Clinical Infectious Diseases · doi:10.1086/597351 · Cited by 165
Allendoerfer, R., & Deepe, G. S. (1998) · PubMed · Cited by 164
Kampmann, B., Whittaker, E., Williams, A., Walters, S., Gordon, A., Martinez-Alier, N., Williams, B., Crook, A. M., Hutton, A.-M., & Anderson, S. T. (2009) · European Respiratory Journal · doi:10.1183/09031936.00153408 · Cited by 164
Self-citationSecreted Lymphotoxin-α Is Essential for the Control of an Intracellular Bacterial Infection
Roach, D. R., Briscoe, H., Saunders, B., France, M. P., Riminton, S., & Britton, W. J. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.2.239 · Cited by 163
Tuberculosis and Treatment with Infliximab
Myers, A., Clark, J., & Foster, H. (2002) · New England Journal of Medicine · doi:10.1056/nejm200202213460815 · Cited by 155
Self-citationPerformance of Tests for Latent Tuberculosis in Different Groups of Immunocompromised Patients
Richeldi, L., Losi, M., D’Amico, R., Luppi, M., Ferrari, A., Mussini, C., Codeluppi, M., Cocchi, S., Prati, F., Paci, V., et al. (2009) · CHEST Journal · doi:10.1378/chest.08-2575 · Cited by 154
Ehlers, S., Hölscher, C., Scheu, S., Tertilt, C., Hehlgans, T., Suwinski, J., Endres, R., & Pfeffer, K. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.5210 · Cited by 149
Self-citationReactivation of Latent Tuberculosis Infection in TNF-Deficient Mice
Botha, T., & Ryffel, B. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.6.3110 · Cited by 149
Braun, J., Baraliakos, X., Listing, J., Fritz, C., Alten, R., Burmester, G. R., Krause, A., Schewe, S., Schneider, M., Sörensen, H., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.075879 · Cited by 144
Stagaki, E., Mountford, W. K., Lackland, D. T., & Judson, M. A. (2008) · CHEST Journal · doi:10.1378/chest.08-1347 · Cited by 144
Mancarella, L., Bobbio‐Pallavicini, F., Ceccarelli, F., Falappone, P. C. F., Ferrante, A., Malesci, D., Massara, A., Nacci, F., Secchi, M. E., Manganelli, S., et al. (2007) · PubMed · Cited by 142
Giamarellos‐Bourboulis, E. J., Pelekanou, E., Antonopoulou, A., Petropoulou, H., Baziaka, F., Karagianni, V., Stavrianeas, N. G., & Giamarellou, H. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08372.x · Cited by 133
Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists
Hamdi, H., Mariette, X., Godot, V., Weldingh, K. N., Hamid, A. M., Prejean, M.-V., Baron, G., Lémann, M., Puéchal, X., Bréban, M., et al. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1994 · Cited by 133
Sester, M., Sester, U., Clauer, P., Heine, G. H., Mack, U., Moll, T., Sybrecht, G. W., Lalvani, A., & Köhler, H. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00586.x · Cited by 116
Self-citationSpohn, G., Guler, R., Johansen, P., Keller, I., Jacobs, M., Beck, M., Röhner, F., Bauer, M., Dietmeier, K., Kündig, T. M., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.7450 · Cited by 110
Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada
Brassard, P., Lowe, A., Bernatsky, S., Kezouh, A., & Suissa, S. (2009) · Arthritis Care & Research · doi:10.1002/art.24476 · Cited by 107
T cell-based diagnosis of childhood tuberculosis infection
Lalvani, A., & Millington, K. A. (2007) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32813e3fd8 · Cited by 106
Ehlers, S., Kutsch, S., Ehlers, E. M., Benini, J., & Pfeffer, K. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.1.483 · Cited by 102
Self-citationMycobacterial Antigens Exacerbate Disease Manifestations in Mycobacterium tuberculosis-Infected Mice
Moreira, A. L., Tsenova, L., Haile Aman, M., Bekker, L.-G., Freeman, S., Mangaliso, B., Schröder, U., Jagirdar, J., Rom, W. N., Tovey, M. G., et al. (2002) · Infection and Immunity · doi:10.1128/iai.70.4.2100-2107.2002 · Cited by 95
Kirchner, S., Holler, E., Haffner, S., Andreesen, R., & Eißner, G. (2004) · Cytokine · doi:10.1016/j.cyto.2004.06.008 · Cited by 91
Adams, L. B., Mason, C. M., Kolls, J. K., Scollard, D. M., Krahenbuhl, J. L., & Nelson, S. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/171.2.400 · Cited by 91
Infectious complications of tumor necrosis factor blockade
Wallis, R. S. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32832dda55 · Cited by 90
Self-citationPink, A., Fonia, A., Allen, M. H., Smith, C. H., & Barker, J. N. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09563.x · Cited by 86
Olleros, M. L., Guler, R., Vesin, D., Parapanov, R., Marchal, G., Martínez-Soria, E., Corazza, N., Pache, J., Mueller, C., & Garcia, I. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62331-0 · Cited by 85
Russo, R. A. G., & Katsicas, M. M. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.090952 · Cited by 83
Feldmann, M., Brennan, F. M., Williams, R. O., Woody, J. N., & Maini, R. N. (2004) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2003.09.010 · Cited by 79
Mori, T. (2009) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-009-0686-8 · Cited by 70
Vincenti, D., Carrara, S., Butera, O., Bizzoni, F., Casetti, R., Girardi, E., & Goletti, D. (2007) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2007.03462.x · Cited by 68
Self-citationPai, M., & Menzies, D. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200701-024ed · Cited by 66
Felley, C. P. (2009) · Swiss Medical Weekly · doi:10.4414/smw.2009.12549 · Cited by 61
Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab.
Belknap, R., Reves, R. R., & Burman, W. J. (2005) · PubMed · Cited by 58
Reguiaï, Z., & Grange, F. (2007) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200708020-00002 · Cited by 47
Safety of anti-TNFalpha therapy in children with juvenile idiopathic arthritis.
Dekker, L., Armbrust, W., Rademaker, C. M. A., Prakken, B. J., Kuis, W., & Wulffraat, N. M. (2004) · PubMed · Cited by 42
Infliximab Therapy in Children and Adolescents with Inflammatory Bowel Disease
Veres, G., Baldassano, R. N., & Mamula, P. (2007) · Drugs · doi:10.2165/00003495-200767120-00005 · Cited by 40
Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review.
Woolacott, N. F., Khadjesari, Z., Bruce, I. N., et al. (2007) · PubMed · Cited by 37
Novel screening tools for latent tuberculosis: time to leave an old friend?
Villiger, P. M., Zellweger, J.-P., & Möller, B. (2009) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328329c6cb · Cited by 14
Self-citation
Cited by
Overview of the IL ‐1 family in innate inflammation and acquired immunity
Dinarello, C. A. (2018) · Immunological Reviews · doi:10.1111/imr.12621 · Cited by 1,866
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
Treating inflammation by blocking interleukin-1 in humans
Dinarello, C. A., & van der Meer, J. W. M. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.008 · Cited by 549
Diel, R., Goletti, D., Ferrara, G., Bothamley, G., Cirillo, D., Kampmann, B., Lange, C., Losi, M., Markova, R., Migliori, G. B., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00115110 · Cited by 544
Self-citationTuberculosis Pathogenesis and Immunity
Philips, J. A., & Ernst, J. D. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132458 · Cited by 416
Metadata
- Authors
- Solovic, I., Sester, M., Gomez-Reino, J. J., Rieder, H. L., Ehlers, S., Milburn, H. J., Kampmann, B., Hellmich, B., Groves, R., Schreiber, S., Wallis, R. S., Sotgiu, G., Schölvinck, E. H., Goletti, D., Zellweger, J. P., Diel, R., Carmona, L., Bartalesi, F., Ravn, P., Bossink, A., Duarte, R., Erkens, C., Clark, J., Migliori, G. B., & Lange, C.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2010-06-07
- Volume
- 36
- Issue
- 5
- Pages
- 1185-1206
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2097362715
- Cited by
- 527
- References
- 131
- FWCI
- 25.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.